Stryker Corporation $SYK Shares Sold by Rothschild Investment LLC

Rothschild Investment LLC trimmed its holdings in Stryker Corporation (NYSE:SYK) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,104 shares of the medical technology company’s stock after selling 1,312 shares during the quarter. Rothschild Investment LLC’s holdings in Stryker were worth $11,514,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Mid American Wealth Advisory Group Inc. acquired a new position in Stryker in the second quarter valued at $26,000. Sachetta LLC grew its holdings in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC increased its position in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares during the period. Ransom Advisory Ltd purchased a new stake in Stryker during the 1st quarter valued at approximately $37,000. Finally, MTM Investment Management LLC acquired a new stake in Stryker during the 2nd quarter worth approximately $38,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 520,500 shares of company stock worth $184,803,065. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent research reports. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 price target on shares of Stryker in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $448.00 price objective on shares of Stryker in a research note on Friday. Truist Financial raised their target price on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday. Evercore ISI lowered their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Thirteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Stock Performance

NYSE:SYK opened at $362.39 on Monday. The firm’s fifty day simple moving average is $371.96 and its 200-day simple moving average is $381.27. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $138.59 billion, a PE ratio of 48.00, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the firm earned $2.87 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.